Epistaxis Clinical Trial
Official title:
Minimally Invasive Control of Epistaxis: Efficacy and Economic Analysis
Epistaxis is a common disorder with 60% of the population suffering from one episode and 10%
of these cases requiring medical attention. Between March 2006 and March 2007, in Calgary,
Alberta, there were 1500 presentations of epistaxis to adult emergency rooms with 7% of
these (105 patients) requiring packing with admission. Common methods to control epistaxis
include, nasal packing (88%), operative arterial ligation (10%), and arterial embolization
(2%). A cost analysis demonstrated that nasal packing had a lower cost compared to
embolization and arterial ligation, and all modalities had similar lengths of stay (Goddard,
Otolaryng Head Neck Surg. 2006). Arterial ligation is the current recommended therapy for
recurrent or refractory epistaxis, with a success rate of 98%. With the advancement of
endoscopic techniques, emergency room Minimally Invasive Control of Epistaxis (M.I.C.E.)
allows for selective packing and cauterization, which provides the patient with retained
function of their nasal cavity and prevents a hospital admission, resulting in significant
cost savings.
Hypothesis:
Does the M.I.C.E. procedure provide significant cost savings compared to operative
sphenopalatine artery ligation? Null hypothesis is that there is no difference in hospital
admission rates between M.I.C.E. and operative sphenopalatine artery ligation.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05334017 -
Xylometazoline and Cocaine for Nasal Vasoconstriction
|
Phase 4 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Recruiting |
NCT01886768 -
Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
|
N/A | |
Recruiting |
NCT00390663 -
A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
|
Phase 4 | |
Suspended |
NCT04054687 -
Intranasal TXA for Anterior Epistaxis in the Emergency Department
|
Phase 2 | |
Completed |
NCT02285634 -
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
|
N/A | |
Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT00793117 -
The Effect of Packing in Post Operative Management of FESS
|
Phase 4 | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05281952 -
Medico-economic Evaluation of Management Strategies for Severe Epistaxis
|
N/A | |
Completed |
NCT03360045 -
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
|
Phase 4 | |
Completed |
NCT04279288 -
The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures
|
N/A | |
Completed |
NCT03912051 -
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
|
N/A | |
Not yet recruiting |
NCT02677467 -
Correlation Between Epistaxis and Cardiovascular Disease
|
N/A | |
Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
Terminated |
NCT01051427 -
Control of Epistaxis With Surgiflo
|
N/A | |
Completed |
NCT00863356 -
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
|
N/A | |
Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
Not yet recruiting |
NCT05343650 -
NOVAPAK Nasal Packing in Shellfish Allergic Patients
|
Phase 4 |